Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 3,975,536

« Back to Dashboard

Summary for Patent: 3,975,536

Title: Composition
Abstract:There is described a composition comprising a substantially clear, sterile aqueous solution containing as active ingredient a therapeutically useful proportion of 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof, or 5,5'-[[5,5'-(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-yl]]t etrazole, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof. The composition is indicated for the treatment of conditions of the eye and the nose.
Inventor(s): Stevenson; Neil Arthur (Loughborough, EN), Wardell; George (Loughborough, EN)
Assignee: Fisons Limited (London, EN)
Application Number:05/471,141
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 3,975,536

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14529/71May 12, 1971
57169/71Dec 9, 1971
25237/73May 25, 1973
25238/73May 25, 1973
26649/73Jun 5, 1973
33325/73Jul 12, 1973

International Patent Family for Patent: 3,975,536

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia465305► Subscribe
Australia4208072► Subscribe
Belgium782981► Subscribe
Canada1000201► Subscribe
Cyprus955► Subscribe
Germany2223237► Subscribe
Germany2266025► Subscribe
Germany2425281► Subscribe
Denmark131324► Subscribe
France2139872► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: